Chenling Xu
YOU?
Author Swipe
Engineering highly active nuclease enzymes with machine learning and high-throughput screening Open
Optimizing enzymes to function in novel chemical environments is a central goal of synthetic biology, but optimization is often hindered by a rugged fitness landscape and costly experiments. In this work, we present TeleProt, a machine lea…
View article: Consensus prediction of cell type labels in single-cell data with popV
Consensus prediction of cell type labels in single-cell data with popV Open
Cell-type classification is a crucial step in single-cell sequencing analysis. Various methods have been proposed for transferring a cell-type label from an annotated reference atlas to unannotated query datasets. Existing methods for tran…
View article: GENTANGLE: integrated computational design of gene entanglements
GENTANGLE: integrated computational design of gene entanglements Open
Summary The design of two overlapping genes in a microbial genome is an emerging technique for adding more reliable control mechanisms in engineered organisms for increased stability. The design of functional overlapping gene pairs is a ch…
Engineering of highly active and diverse nuclease enzymes by combining machine learning and ultra-high-throughput screening Open
Optimizing enzymes to function in novel chemical environments is a central goal of synthetic biology, but optimization is often hindered by a rugged, expansive protein search space and costly experiments. In this work, we present TeleProt,…
Figure S1 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S1. Phenotype of T cells (at isolation) and CAR T cells (pre-infusion).
Figure S2 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S2.SUV39H1 disruption does not improve anti-tumor efficacy of non-functional/non-specific CAR.
Figure S6 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S6.Increased proliferation and reduced effector function in 1928z CAR T cells upon SUV39H1 disruption.
Figure S7 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S7. SUV39H1 disruption, over time, improves expansion and cytolytic capacity of CAR T cells under conditions of repeated stimulation.
Figure S9 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S9. Enhanced TCF1 and LEF1 expression in SUV39H1-edited CAR T cells under conditions of repeated stimulation.
Table S1 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Key Resources Table
Table S1 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Key Resources Table
Data from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Suboptimal functional persistence limits the efficacy of adoptive T-cell therapies. CD28-based chimeric antigen receptors (CAR) impart potent effector function to T cells but with a limited lifespan. We show here that the genetic disruptio…
Figure S4 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S4. Off-target editing of the SUV39H1 gRNA.
Figure S5 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S5. SUV39H1 disruption improves anti-tumor efficacy of multiple CAR designs in a prostate cancer model.
Figure S9 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S9. Enhanced TCF1 and LEF1 expression in SUV39H1-edited CAR T cells under conditions of repeated stimulation.
Figure S5 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S5. SUV39H1 disruption improves anti-tumor efficacy of multiple CAR designs in a prostate cancer model.
Figure S7 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S7. SUV39H1 disruption, over time, improves expansion and cytolytic capacity of CAR T cells under conditions of repeated stimulation.
Figure S2 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S2.SUV39H1 disruption does not improve anti-tumor efficacy of non-functional/non-specific CAR.
Figure S1 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S1. Phenotype of T cells (at isolation) and CAR T cells (pre-infusion).
Data from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Suboptimal functional persistence limits the efficacy of adoptive T-cell therapies. CD28-based chimeric antigen receptors (CAR) impart potent effector function to T cells but with a limited lifespan. We show here that the genetic disruptio…
Figure S8 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S8. SUV39H1 disruption enhances CAR T cell persistence.
Figure S8 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S8. SUV39H1 disruption enhances CAR T cell persistence.
Figure S3 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S3. CAR T cell inhibitory receptor expression.
Figure S3 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S3. CAR T cell inhibitory receptor expression.
Figure S4 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S4. Off-target editing of the SUV39H1 gRNA.
Figure S6 from Disruption of <i>SUV39H1</i>-Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Figure S6.Increased proliferation and reduced effector function in 1928z CAR T cells upon SUV39H1 disruption.
Disruption of <i>SUV39H1</i> -Mediated H3K9 Methylation Sustains CAR T-cell Function Open
Suboptimal functional persistence limits the efficacy of adoptive T-cell therapies. CD28-based chimeric antigen receptors (CAR) impart potent effector function to T cells but with a limited lifespan. We show here that the genetic disruptio…